Idorsia’s once-daily TRYVIO™ (aprocitentan) is now available in the U.S., advancing treatment options for millions of patients with difficult-to-control hypertension

• Once-daily TRYVIO, now available to prescribe in the U.S., is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other medications.
• TRYVIO is the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of systemic hypertension.
• Idorsia (SIX:) to present new data on TRYVIO at American Heart Association’s Scientific Sessions and will have a TRYVIO commercial and medical booth at #1705

RADNOR, Pa., Nov. 15, 2024 /PRNewswire/ — Idorsia Pharmaceuticals U.S. Inc. today announced that TRYVIO™ (aprocitentan) is now available in the U.S. for the treatment of hypertension, in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs. In the United States, nearly 120 million adults “ or about half of the adult population “ have hypertension.¹ Of those diagnosed and treated with existing standards of care, only ~50% achieve blood pressure control at a goal of 1

TRYVIO was approved by the U.S. FDA based on the Phase 3 PRECISION trial which demonstrated that TRYVIO reduced systolic blood pressure by 15.4  mm Hg from baseline at 4 weeks (primary endpoint) when added to standardized background therapy of at least three antihypertensive drugs, including a diuretic (see full PRECISION phase 3 study design below).² TRYVIO was well-tolerated, and its safety profile established over a 48-week study. The most frequently reported adverse reactions were edema/fluid retention and anemia.²  TRYVIO has a boxed warning for embryo-fetal toxicity.  

Tosh Butt, President and General Manager of Idorsia U.S. commented:
“Today, hypertension is the leading modifiable risk factor for cardiovascular disease and mortality in the world. TRYVIO’s availability in the U.S. is an important milestone for the millions of patients who require novel  approaches to control their blood pressure. Idorsia has delivered a treatment addressing a previously unaddressed therapeutic pathway in systemic hypertension for the first time in over three decades, giving hope to patients whose existing therapies are not adequate. We are enormously proud to bring this important medication to the medical community and the patients they serve.”

Michael A. Weber, MD, Professor of Medicine, Division of Cardiovascular Medicine State University of New York, commented:
“Uncontrolled hypertension…